Abstract
Background: Abstract: The objective of the present work was to prepare and optimize the loteprednoletabonate (LE) loaded poly (D,L-lactide co-glycolide) (PLGA) polymer based nanoparticle carrier. The review on recent patents (US9006241, US20130224302A1, US2012/0028947A1) assisted in the selection of drug and polymer for designing nanoparticles for ocular delivery applications.
Methods: The nanoparticles were prepared by solvent evaporation followed by high speed homogenization. Biodegradable polymer PLGA (50:50) grade was utilized to develop various formulations with different drug:polymer ratio. A Box-Behnken design with 33 factorial design was selected for the present study and 17 runs were carried out in totality. The influence of various process variables (viz., polymer concentration, homogenization speed and sonication time) on the characteristics of nanoparticles including the in vitro drug release profile were studied. Results: The nanoparticulate formulations were evaluated for mean spherical diameter, polydispersity index (PDI), zeta potential, surface morphology, drug entrapment and in-vitro drug release profile. The entrapment efficiency, drug loading and mean particle size were found to be 96.31±1.68 %, 35.46±0.35 % and 167.6±2.1 nm respectively. Conclusion: The investigated process and formulation variables were found to have significant effect on the particle size, drug loading (DL), entrapment efficiency (EE), and in vitro drug release profile. A biphasic in vitro drug release profile was apparent from the optimized nanoparticles (NPs) for 24 hours.Keywords: Box-behnken design, corticosteroid, loteprednol etabonate, nanoparticle, optimization, ocular delivery, PLGA, surface response methodology.
Current Drug Delivery
Title:Loteprednol Etabonate Nanoparticles: Optimization via Box-Behnken Design Response Surface Methodology and Physicochemical Characterization
Volume: 14 Issue: 5
Author(s): Abhishek K. Sah and Preeti K. Suresh*
Affiliation:
- University Institute of Pharmacy, Faculty of Technology, Pt. Ravishankar Shukla University, Raipur-492010, Chhattisgarh,India
Keywords: Box-behnken design, corticosteroid, loteprednol etabonate, nanoparticle, optimization, ocular delivery, PLGA, surface response methodology.
Abstract: Background: Abstract: The objective of the present work was to prepare and optimize the loteprednoletabonate (LE) loaded poly (D,L-lactide co-glycolide) (PLGA) polymer based nanoparticle carrier. The review on recent patents (US9006241, US20130224302A1, US2012/0028947A1) assisted in the selection of drug and polymer for designing nanoparticles for ocular delivery applications.
Methods: The nanoparticles were prepared by solvent evaporation followed by high speed homogenization. Biodegradable polymer PLGA (50:50) grade was utilized to develop various formulations with different drug:polymer ratio. A Box-Behnken design with 33 factorial design was selected for the present study and 17 runs were carried out in totality. The influence of various process variables (viz., polymer concentration, homogenization speed and sonication time) on the characteristics of nanoparticles including the in vitro drug release profile were studied. Results: The nanoparticulate formulations were evaluated for mean spherical diameter, polydispersity index (PDI), zeta potential, surface morphology, drug entrapment and in-vitro drug release profile. The entrapment efficiency, drug loading and mean particle size were found to be 96.31±1.68 %, 35.46±0.35 % and 167.6±2.1 nm respectively. Conclusion: The investigated process and formulation variables were found to have significant effect on the particle size, drug loading (DL), entrapment efficiency (EE), and in vitro drug release profile. A biphasic in vitro drug release profile was apparent from the optimized nanoparticles (NPs) for 24 hours.Export Options
About this article
Cite this article as:
Sah K. Abhishek and Suresh K. Preeti*, Loteprednol Etabonate Nanoparticles: Optimization via Box-Behnken Design Response Surface Methodology and Physicochemical Characterization, Current Drug Delivery 2017; 14 (5) . https://dx.doi.org/10.2174/1567201813666160801125235
DOI https://dx.doi.org/10.2174/1567201813666160801125235 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress in Cationic Lipid-Mediated Gene Transfection: A Series of Bio- Inspired Lipids as an Example
Current Gene Therapy 1α ,25(OH)2-Vitamin D3 and 17β-Estradiol: Two Steroid Partners Acting in Skeletal Muscle
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Is Human Immunodeficiency Virus-Mediated Dementia an Autophagic Defect that Leads to Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Biomarkers of Immunity and Inflammation for use in Nutrition Interventions: International Life Sciences Institute European Branch Work on Selection Criteria and Interpretation
Endocrine, Metabolic & Immune Disorders - Drug Targets BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimers Disease Therapies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Withdrawal Notice: Emerging Novel Coronavirus is a Global Threat: Insight in the Biology of COVID-19 and its Hijacking Process of Hosts’ Cell
Current Pharmaceutical Design Effects of Resveratrol and Other Polyphenols on the Most Common Brain Age-Related Diseases
Current Medicinal Chemistry Depsipeptide (FK228) as a Novel Histone Deacetylase Inhibitor: Mechanism of Action and Anticancer Activity
Mini-Reviews in Medicinal Chemistry Busulphan in Blood and Marrow Transplantation: Dose, Route, Frequency and Role of Therapeutic Drug Monitoring
Current Clinical Pharmacology MicroRNAs: A Novel Therapeutic Target for Schizophrenia
Current Pharmaceutical Design Modern Developments in the Spray-Drying Industries
Recent Patents on Materials Science GABAB Receptors-Associated Proteins: Potential Drug Targets in Neurological Disorders?
Current Drug Targets New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design Roles of NHERF1/EBP50 in Cancer
Current Molecular Medicine High-Throughput Screening of Neuronal Cl- Channels: Why and How?
Current Neuropharmacology Alzheimer Disease and the Role of Free Radicals in the Pathogenesis of the Disease
CNS & Neurological Disorders - Drug Targets The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets The Role of TMP21 in Trafficking and Amyloid-β Precursor Protein (APP) Processing in Alzheimer’s Disease
Current Alzheimer Research Model Systems for Pulmonary Infectious Diseases: Paradigms of Anthrax and Tuberculosis
Current Topics in Medicinal Chemistry Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry